TRRITrinity Resources Inc.

About Trinity Resources Inc. (TRRI)

Trinity Resources Inc. (TRRI) is a Biotechnology company headquartered in Las Vegas, NV, United States whose shares trade over-the-counter on the Pink tier.

On December 16, 2022, Trinity Resources Inc. announced it has applied for name and symbol change to reflect its new name of ALZEX NEUROPHARMA INC. and is awaiting final approval from FINRA of its Corporate Action. On June 30, 2022, the Company entered into an asset purchase agreement to purchase the assets and intellectual property of Alzex Biomedical Group Inc. ("Alzex Bio"), a company incorporated under the laws of the Province of British Columbia, Canada. The purchase price was 10,000,000 restricted shares of our Series A and Series B Convertible Preferred Stock, which were subsequently issued on August 5, 2022. The Company will also advance the sum of $150,000 to Alzex Bio to be disbursed with mutual agreement for settlement of certain outstanding liabilities of Alzex Bio as well as to further secure, and refile where warranted, additional patent protection covering the intellectual property. Under the terms of the asset purchase agreement, the shareholders of the Company's Series A and Series B Convertible Preferred Stock will retain security over the intellectual property until we have successfully raised the first five million dollars ($5,000,000 USD) for deployment towards the clinical development of the acquired Alzex Bio assets, at which point the preferred shares will automatically convert to common shares.

Products and services

Alzex Neuropharma Inc. is an emerging biopharmaceutical company which, after acquiring the assets of Alzex Bio, a Canadian research and development company including a general patent (Wo2006/103120) which has been granted by The Patent Cooperation Treaty (PCT), an international patent law treaty with more than 157 Contracting States including the European Union, United States, United Kingdom and Israel is planning, upon securing sufficient funding, to continue research and development targeting innovative treatments of brain diseases. This will be spearheaded by development team members from Alzex Bio and in collaboration with partnerships including INSA (Institut National des Sciences Appliquées) a major French academic engineering and research institute, and the French biotech Seabud to ensure the chemical development of its new drugs currently dedicated to the symptomatic treatment of Alzheimer’s Disease but can be applied to other neurological diseases due to its platform technology.

TRRI key facts

Ticker symbol

TRRI

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Las Vegas, NV, United States

Country of incorporation

US

Year of incorporation

2022

Employees

2

Estimated market cap

$90.3K (as of Apr 15, 2025)

Shares outstanding

1,505,268

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Quarterly Report (Jun 30, 2024)

Trinity Resources Inc. leadership

• Robert Rosner — President, CEO, Secretary
• Christopher Malone — CFO

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with T